Staff Reports
The United States just refused to bless a United Nations political declaration on pandemic prevention and preparedness. CDC Director Erica Schwartz told the UN high‑level meeting that the U.S. could not support the text in full. That single move stopped the document from being adopted by consensus and put a big question mark over global plans to lock in pandemic rules.
What the U.S. objected to — and why it matters
Schwartz said the draft included “divisive ideologies” that do not have clear definitions and pointed to an unfinished annex on Pathogen Access and Benefit Sharing, often called PABS. In plain English, PABS would set rules for sharing virus samples, genetic data, and how vaccines and tools get shared or paid for. Those are big, thorny issues. By withholding support, the U.S. forced countries to either keep negotiating or take the fight to the full UN later on.
PABS, sovereignty, and why conservatives should care
PABS is the core fight. If it sets a rule that weakens U.S. control over samples or technology, that could limit how America protects its people or how companies profit from their own innovations. National sovereignty is not a quaint idea. It means our experts, labs, and companies are under U.S. rules, not a distant UN process. The U.S. pushback preserved that space. That’s the smart, cautious play — not a surrender to global mandates.
Gain‑of‑function research and the U.S. policy stance
At the same meeting, CDC Director Schwartz urged other nations to follow U.S. steps to restrict federal funding for risky “gain‑of‑function” research. The administration has already put limits on certain high‑risk experiments. That policy explains part of why the U.S. balked at the declaration: Washington doesn’t want an international text that locks it into rules or programs that could conflict with domestic safeguards. Better to disagree now than to be boxed in later.
What comes next and the political angle
Because consensus failed, the declaration can be reworked or moved to a later UN vote. Expect more pressure from WHO officials and global health lobbyists to finish PABS and get a concrete treaty. And yes — if Democrats control Washington down the road, they may try to sign on to stronger global rules. For now, the U.S. stance defends national control and sensible caution. That should please anyone who thinks American law and American labs should answer to American leaders — not to technocrats looking for one‑size‑fits‑all fixes.
